Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obrixtamig plus pumitamig with or without carboplatin and etoposide in extensive-stage small cell lung carcinoma
jRCT2061260071Phase 2Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of obrixtamig and pumitamig in small cell lung cancer (SCLC) (2 cohorts), sponsored by Boehringer Ingelheim. Primary endpoint: Safety, tolerability and early clinical efficacy. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
obrixtamigpumitamig
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2061260071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061260071.